To the Editor Dr Meissner1 explored the consequences of vaccine pricing and costs for US immunization policy. New vaccines against serogroup B meningococcal disease, an extremely serious but rare condition, demonstrate the challenges government advisors face fulfilling their dual responsibilities of evaluating scientific and clinical evidence and of considering economic factors when developing vaccination recommendations.2 Because of the high costs of these vaccines and the small number of hospitalizations and deaths they could prevent, Meissner suggests that the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) should recommend against their use instead of its current Category B (“permissive”) recommendation that encourages joint decision making by clinicians and patients on a case-by-case basis.
Schwartz JL. Vaccine Pricing and US Immunization Policies. JAMA. 2016;316(2):226. doi:10.1001/jama.2016.6307